After a meeting of the Slovenian Council for Dementia Management, on 2 November, at the Office of the President of the Republic of Slovenia, the Slovenian Ministry of Health launched a public debate regarding the proposed National Dementia Strategy until 2030. The Strategy was prepared by an interdisciplinary working group, whose members include Štefanija L. Zlobec, president of Alzheimer Slovenia.
We invite you to register to access on-demand videos and posters of the 32nd Alzheimer Europe Conference. If you didn't get a chance to participate in the event in October, but you would like to check out some of the fantastic presentations, you can gain access to our on-demand content for a reduced price of EUR 50!
Unfortunately, Roche had to present disappointing results at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Francisco. Its GRADUATE I and II clinical trials of gantenerumab failed to meet their primary and secondary endpoints and as a consequence of these negative results, the company announced that it would be discontinuing most of its global clinical trials of gantenerumab.
Eisai and Biogen announced positive results from the Phase III Clarity AD trial of lecanemab for the treatment of early Alzheimer’s disease at the CTAD 2022 conference in San Francisco. The trial met its primary and secondary endpoints at 18 months, showing both a statistically significant reduction of cognitive decline and reduction in amyloid plaque burden.